Article
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
The New England journal of medicine - 2 Jan 2020
Ramalingam Suresh S, Vansteenkiste Johan, Planchard David, Cho Byoung Chul, Gray Jhanelle E, Ohe Yuichiro, Zhou Caicun, Reungwetwattana Thanyanan, Cheng Ying, Chewaskulyong Busyamas, Shah Riyaz, Cobo Manuel, Lee Ki Hyeong, Cheema Parneet, Tiseo Marcello, John Thomas, Lin Meng-Chih, Imamura Fumio, Kurata Takayasu, Todd Alexander, Hodge Rachel, Saggese Matilde, Rukazenkov Yuri, Soria Jean-Charles
Abstract excerpt
BACKGROUND: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). The trial showed longer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.